AstraZeneca India gets Enhertu nod for early-stage breast cancer
The drug regulator cleared neoadjuvant use in HER2-positive Stage II/III breast cancer, expanding the addressable pool for the company's top oncology product, which already drove over ₹22,756 mn in FY26 revenue.
— 5 earlier stories on Astrazeneca Pharma India Ltd. →What's new
- CDSCO approved Enhertu for neoadjuvant treatment of HER2-positive Stage II/III breast cancer.
- The nod adds a pre-surgery indication to Enhertu's existing first-line metastatic approval.
- AstraZeneca India secured 11 regulatory approvals in FY26 and sits debt-free with ₹4.5 bn net cash.
Why this matters
Enhertu already accounts for a large share of oncology sales, which are three-quarters of the company's product revenue. This indication shift from advanced to early-stage breast cancer widens the treatable patient base significantly, a textbook volume lever for a drug with over $3 bn in global sales last year.
What we're watching
- How quickly the neoadjuvant indication translates into tender wins and hospital formulary placements.
- Competing antibody-drug conjugates from Roche and Daiichi Sankyo in the same space.
- Whether AstraZeneca India files for additional early breast cancer settings (e.g., adjuvant) in the future.
The full read
AstraZeneca Pharma India just widened the runway for its biggest growth engine. The drug regulator cleared Enhertu for neoadjuvant use in HER2-positive Stage II/III breast cancer. That is pre-surgery treatment, not just advanced disease. Hardly a marginal label expansion. The company's FY26 numbers tell the story: revenue hit ₹22,756 mn, up 33%, with oncology delivering three-quarters of product sales. Enhertu already had a first-line metastatic nod from June; now it can reach patients earlier. The balance sheet adds confidence: debt-free with ₹4.5 bn in net cash and 11 regulatory approvals logged last year. For a stock trading at a trailing P/E of 112, growth needs to keep coming. This approval gives it another gear.
Questions answered
- What does 'neoadjuvant' mean in this context?
- Neoadjuvant therapy is given before surgery to shrink the tumor and improve surgical outcomes. For HER2-positive Stage II/III breast cancer, Enhertu can now be used as a pre-operative treatment, expanding its use beyond advanced/metastatic stages.
- How significant is Enhertu to AstraZeneca Pharma India's revenue?
- Enhertu is one of three key oncology products driving growth. Oncology contributed roughly 75% of total product sales in FY26, and the company's overall revenue rose 33% to ₹22,756 mn.
- What is the competitive landscape for Enhertu in India?
- Enhertu competes with other HER2-targeted therapies like Roche's Kadcyla and Perjeta. Its unique antibody-drug conjugate mechanism and strong global data give it a differentiation edge.
- Does the company have other recent regulatory wins?
- Yes, AstraZeneca India received 11 regulatory approvals in FY26, including earlier Enhertu nods for first-line HER2 breast cancer and Fasenra for hypereosinophilic syndrome.
- How healthy is AstraZeneca India's balance sheet?
- The company is debt-free with net cash of ₹4.5 billion. This strong financial position supports investment in new product launches and market expansion.
Astrazeneca Pharma India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ASTRAZEN →- 28 Jul 2026 · 1:24 PM IST AstraZeneca India gets Enhertu nod for early-stage breast cancer
- 12d ago AstraZeneca India gets CDSCO nod for Fasenra in rare hypereosinophilic syndrome
- 47d ago AstraZeneca India gets Enhertu nod for first-line HER2 breast cancer
- 63d ago AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
- 63d ago AstraZeneca Pharma India profit rises to ₹1.9 billion